Urea motif containing compounds and derivatives thereof as antibacterial drugs

A method for the treatment of a bacterial disease, said method comprising administering a compound to a subject having been diagnosed with the bacterial disease, said compound having a structure according to Formula II

• wherein
• R1 is;
• R2 is (C1-C6)alkyl or (C1-C6) haloalkyl;
• R13 is selected from the group consisting of hydrogen, (C1-C6)alkyl, (C1-C6) haloalkyl and halogen;
• and
• X is O or S;
• or a pharmaceutically acceptable salt, solvate or hydrate thereof,
• wherein the bacterial disease is caused by at least one bacteria selected from the group consisting of Listeria monocytogenes, Listeria welshimeri, Staphylococcus aureus, MRSA and clinical isolates thereof, Vancomycin-intermediate Staphylococcus aureus, Vancomycin-resistant Staphylococcus aureus, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus epidermidis, Staphylococcus saprophyticus, Staphylococcus lugdunensis, Staphylococcus schleiferi, Staphylococcus caprae, Streptococcus pneumoniae, Streptococcus viridans, Streptococcus pyogenes, Streptococcus agalactiae, Enterococcus faecalis, Enterococcus faecium, Bacillus licheniformis, Bacillus subtilis, Bacillus anthracis, Bacillus cereus, Bacillus thuringiensis, Bacillus larvae, Mycobacterium tuberculosis, Mycobacterium bovis, Mycobacterium leprae, Mycobacterium ulcerans, Mycobacterium kanasasii, Mycobacterium avium, Mycobacterium paratuberculosis, Mycobacterium scrofulaceam, Mycobacterium microti, Mycobacterium africanum, Mycobacterium canettii, Mycobacterium intracellulare, Mycobacterium simiae, Mycobacterium szulgai, Mycobacterium xenopi, Mycobacterium fortuitum, Mycobacterium chelonei, Mycobacterium marinum, Nocardia asteroids, Rhodococcus equi and Burkholderia thailandensis.

A method for the treatment of a bacterial disease, said method comprising administering a compound to a subject having been diagnosed with the bacterial disease, said compound being selected from the group consisting of

• 1-(4-chloro-3-methylphenyl)-3-(2,2-difluorobenzo [d][1,3]dioxol-5-yl) urea,
• 1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(2,2-difluorobenzo [d][1,3]dioxol-5-yl) urea,
• 1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(2,2-difluorobenzo [d][1,3]dioxol-5-yl)thiourea,
• and
• 1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(2,2-difluorobenzo [d][1,3]dioxol-4-yl) urea,
• wherein the bacterial disease is caused by at least one bacteria selected from the group consisting of Listeria monocytogenes, Listeria welshimeri, Staphylococcus aureus, MRSA and clinical isolates thereof, Vancomycin-intermediate Staphylococcus aureus, Vancomycin-resistant Staphylococcus aureus, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus epidermidis, Staphylococcus saprophyticus, Staphylococcus lugdunensis, Staphylococcus schleiferi, Staphylococcus caprae, Streptococcus pneumoniae, Streptococcus viridans, Streptococcus pyogenes, Streptococcus agalactiae, Enterococcus faecalis, Enterococcus faecium, Bacillus licheniformis, Bacillus subtilis, Bacillus anthracis, Bacillus cereus, Bacillus thuringiensis, Bacillus larvae, Mycobacterium tuberculosis, Mycobacterium bovis, Mycobacterium leprae, Mycobacterium ulcerans, Mycobacterium kanasasii, Mycobacterium avium, Mycobacterium paratuberculosis, Mycobacterium scrofulaceam, Mycobacterium microti, Mycobacterium africanum, Mycobacterium canettii, Mycobacterium intracellulare, Mycobacterium simiae, Mycobacterium szulgai, Mycobacterium xenopi, Mycobacterium fortuitum, Mycobacterium chelonei, Mycobacterium marinum, Nocardia asteroids, Rhodococcus equi and Burkholderia thailandensis.